We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Draft Guidance Outlines Statistical Considerations for Proving Biosimilarity
FDA Draft Guidance Outlines Statistical Considerations for Proving Biosimilarity
Biosimilar sponsors should take a risk-based approach when assessing similarity of a reference product’s quality attributes, the FDA said in new draft guidance — pitched as part of the agency’s effort to lower drug prices.